[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-distress-syndrome-rds\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-distress-syndrome-rds":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,61,85,120,157,186,216,242,262,289,308,332,361,384,411],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100640195","feasibility-of-protocolised-analgosedation-in-ecmo-100640195",false,"NCT07580781","Feasibility of Protocolised Analgosedation in ECMO","Feasibility of a Cluster Randomised Control Trial Evaluating a Co-designed Analgosedation Protocol in Extracorporeal Membrane Oxygenation (ECMO) Patients","ECMO-SED","Inclusion Criteria:\n\n* Aged 18 years and older\n* Receiving IV continuous infusions of analgosedation medication\n* Receiving ECMO treatment\n\nExclusion Criteria:\n\n* There will be no exclusion criteria as analgosedation management is routine for all adult ECMO patients.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.\n\nA sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.\n\nHowever, there are no protocols for giving sedation to ECMO patients in research papers. Investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.\n\nAims:\n\nTo see whether it is possible to run a trial that compares using a sedation protocol against usual care.\n\nDesign\u002Fmethods:\n\nThirty to 60 ECMO patients will be chosen and will be put into one of two groups. One group will receive usual care, and the other will receive care using the sedation protocol. The investigators will collect information from both groups to find out if the study design works and how many patients agree to take part.\n\nPatient and public involvement\u002Fengagement:\n\nThe investigators received feedback from patients and family member participants which helped to design this proposal, the lay summary and what to measure in a trial. They will advise how the investigators should review study findings, and support sharing of results to the public.\n\nImpact\u002Fdissemination:\n\nThe investigators will share findings through social media, patient charities, research papers and conferences.",[27,28,29,30,31,32,33,34],"Intensive Care (ICU)","Respiratory Distress Syndrome (RDS)","Sedation and Analgesia","Extracorporeal Membrane Oxygenation","Sedation for Mechanical Ventilation","Cardiogenic Shock","Opioid Analgesia","Analgesia",[36,37,38,39,40,41,42,43,44,45,46,47],"extracorporeal membrane oxygenation","sedation","opioid","sedative","analgosedation","mechanical ventilation","ECMO","ICU","Intensive Care Unit","Critical Care","sedation protocol","analgesia","NOT_YET_RECRUITING","2026-05-05",{"date":51,"type":52},"2026-05-12","ACTUAL",{"date":54,"type":21},"2026-09-01",{"date":56,"type":21},"2027-08-31",{"name":58,"class":59},"Guy's and St Thomas' NHS Foundation Trust","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":15,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":84,"locationsCount":60},"100595479","improving-sedation-practice-in-critically-ill-adult-patients-using-a-co-designed-sedation-protocol-100595479","NCT07032987","Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol","Optimising Analgosedation in Extracorporeal Membrane Oxygenation (ECMO) Using a Co-designed Analgosedation Protocol","Stage 1 (multi-centre observational study):\n\nInclusion Criteria:\n\n1. Aged 18 years and older.\n2. Receiving continuous IV infusions of analgosedation (opioids, benzodiazepines, and\u002For propofol).\n3. Receiving ECMO for moderate to severe respiratory failure (PaO2\u002FFiO2 (P\u002FF) ratio \\\u003C20 kilopascals (kPa)) for ≤ 7 days during the week of recruitment.\n4. Non-ECMO ICU patients (control group): must satisfy inclusion criteria 1 and 2, and have received mechanical ventilation for moderate to severe respiratory failure (P\u002FF ratio \\\u003C 20kPa) for at least 48 hours OR mechanical ventilation for cardiovascular disorder (out of hospital cardiac arrest, following cardiothoracic or transplant surgery or percutaneous coronary intervention or acute heart failure).\n\nExclusion Criteria:\n\n1. Anticipated length of ICU stay in recruiting centre for less than 24 hours.\n2. Withdrawal of life-sustaining treatment in the next 24 hours.\n\nStage 2 (mixed methods study):\n\nInclusion Criteria:\n\n1. Healthcare professionals working at one of two ECMO centres (St Thomas' Hospital and Royal Brompton Hospital (part of Guy's and St Thomas' NHS Foundation Trust).\n2. ECMO survivors (patients admitted to ICU and survived ECMO organ support) who have returned home, and recovered.\n3. Family members of ECMO survivors, whose relative is no longer hospitalised.\n\nExclusion Criteria:\n\n1. ECMO survivors currently receiving treatment in hospital.\n2. ECMO survivors with severe cognitive issues (issues with short-term memory and thinking).\n3. ECMO survivors who cannot communicate in English.\n4. Non-ECMO survivors and family members.","100 Years",{"count":70,"type":21},120,"OBSERVATIONAL","Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.\n\nA sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.\n\nHowever, there are no protocols for giving sedation to ECMO patients in research papers. The investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.\n\nAims:\n\n* To describe current sedation use in ECMO patients in the UK and compare to non-ECMO critically ill patients.\n* To develop a sedation protocol for ECMO patients with input from patients, their family, and staff.\n\nDesign\u002Fmethods:\n\nStudy 1:\n\nThe investigators will study how sedation is used in adult ECMO patients and compare with non-ECMO but critically ill patients in the UK. The investigators will collect information on drug doses and pain and sedation scores. The investigators will also ask ECMO centres if they use a sedation protocol to adjust sedation doses. This information will be helpful for the design of the protocol in study 2.\n\nStudy 2:\n\nThe investigators will design a sedation protocol with input from patients, family, and staff. The investigators will organise meetings to share experiences and agree on what to include in the protocol that is considered acceptable and safe. The investigators will then assess if the protocol is safe and acceptable with staff outside the co-design group.\n\nPatient and public involvement\u002Fengagement:\n\nThe investigators received feedback from patients and family members which helped to design this proposal, the lay summary and what to measure in a trial. Patients and family members will continue to help with development of the sedation and trial protocol. They will advise how the investigators should review study findings, and support sharing of results to the public.\n\nImpact\u002Fdissemination:\n\nThe investigators will share findings through social media, patient charities, research papers and conferences.",[74,28,29,75,31,32,33,34],"Intensive Care Medicine","ExtraCorporeal Membrane Oxygenation (ECMO)",[36,37,38,77,40,41,42,43,44,45,46,47],"sedatives","RECRUITING",{"date":80,"type":52},"2026-05-08",{"date":82,"type":52},"2025-11-24",{"date":56,"type":21},{"name":58,"class":59},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100619853","phase-4-calfactant-vs-poractant-alfa-using-a-less-invasive-technique-in-preterm-infants-with-respiratory-distress-syndrome-100619853","NCT07350018","Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome","Comparison of the Efficacy of Calfactant and Poractant Alfa Surfactants Administered by a Less Invasive Surfactant Administration Technique in Preterm Infants With Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Born at a participating study center hospital.\n* Gestational age between 24 1\u002F7 and 29 6\u002F7 weeks (\\\u003C30 0\u002F7 weeks).\n* Postnatal age within the first 6 hours of life.\n* Being on non-invasive respiratory support.\n* Presence of clinical and radiological findings consistent with respiratory distress syndrome (RDS).\n* Indication for surfactant therapy defined as a requirement for FiO₂ \\>30% to achieve target oxygen saturation (SpO₂ 90-94%) while receiving noninvasive respiratory support with a minimum pressure of 6 cmH₂O.\n* Written informed consent obtained from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Infants who were intubated for any reason before the decision to administer surfactant.\n* Severe birth asphyxia, defined as the need for advanced resuscitation after birth, 10th minute Apgar score ≤5, and arterial blood gas within the first hour of life showing pH \\\u003C7.0 and base excess (BE) ≤-12.\n* Presence of major congenital anomalies.\n* Respiratory distress due to causes other than respiratory distress syndrome (RDS).\n* Congenital heart disease.\n* Congenital diaphragmatic hernia.\n* Pulmonary hypoplasia.\n* Chromosomal abnormalities.\n* Presence of pneumothorax.\n* Lack of informed consent.\n* Neonatal seizures presence.\n* Postnatal age greater than 6 hours.\n* Infants born outside of gestational weeks 24 1\u002F7 - 29 6\u002F7.\n* Requirement for invasive mechanical ventilation at enrollment.\n* Infants receiving noninvasive respiratory support with an FiO₂ requirement \\\u003C0.30.","0 Hours","6 Hours",{"count":95,"type":21},234,[97],"PHASE4","Respiratory distress syndrome (RDS) is a common cause of respiratory failure in preterm infants and is frequently treated with surfactant therapy. With the increasing use of noninvasive ventilation, less invasive methods of surfactant administration have been developed. In the technique known as Less Invasive Surfactant Administration (LISA), surfactant is delivered into the trachea through a thin catheter, without the need for endotracheal intubation. This approach may reduce lung injury and improve respiratory outcomes in spontaneously breathing preterm infants. This multicenter, prospective, randomized study aims to compare the clinical effectiveness of poractant alfa and calfactant when administered using the LISA technique in preterm infants born at less than 30 weeks' gestation with RDS who are not intubated. The study will evaluate short-term outcomes, including the need for intubation, repeat surfactant administration, and respiratory support during the first 72 hours of life, as well as longer-term outcomes such as bronchopulmonary dysplasia and other neonatal morbidities.",[100,28,101],"Respiratory Distress Syndrome in Premature Infants","Surfactant",[103,104,105,106,107,108,109],"Respiratory Distress Syndrome","Premature infant","Poractant alfa","Calfactant","surfactant treatment","Less Invasive Surfactant Administration","LISA","2026-04-27",{"date":112,"type":52},"2026-04-28",{"date":114,"type":52},"2026-01-20",{"date":116,"type":21},"2027-02-20",{"name":118,"class":59},"Uludag University",5,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":129,"studyType":71,"phases":4,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100635248","surfactant-administration-methods-in-preterm-infants-with-rds-a-swedish-cohort-study-100635248","NCT07550218","Surfactant Administration Methods in Preterm Infants With RDS: A Swedish Cohort Study","A Prospective Observational Study of Surfactant AdministrationMethods for Preterm Infants With Respiratory Distress SyndromeWith Long-term Follow-up in the Swedish Neonatal Quality Register","Inclusion Criteria:\n\n* Patient has received surfactant by any administration method\n* Gestational age below 37 weeks'\n* First surfactant treatment given before 48 hours of age\n* Confirmed or suspected diagnosis of respiratory distress syndrome (RDS)\n\nExclusion Criteria:\n\n• Not fulfilling above inclusion criteria",{"count":128,"type":21},300,"6 Years","The goal of this observational study is to evaluate different methods of surfactant administration in preterm infants with respiratory distress syndrome (RDS). Preterm infants often have immature lungs and a deficiency of surfactant, a substance that helps keep the lungs open and supports oxygen exchange.Surfactant can be delivered to the lungs using different techniques, including INSURE (brief intubation), LISA (via a thin catheter), SALSA (via a laryngeal mask airway), and traditional administration via endotracheal intubation followed by mechanical ventilation. The main question this study aims to answer is:Which method of surfactant administration is associated with better clinical outcomes in preterm infants with RDS?The study will prospectively collect clinical data on infants receiving surfactant as part of standard care, with long-term follow-up using data from the Swedish Neonatal Quality Register. The results are intended to be used to inform the design of a future randomized multicenter study.",[132,133,28,134,135],"Respiratory Distress Syndrome (& [Hyaline Membrane Disease])","Respiratory Distress Syndrome (Neonatal)","Respiratory Distress Syndrome of Newborn","Respiratory Distress Syndrome in Premature Infant",[137,138,139,140,141,142,109,143,144,145,146,147,103],"Preterm infants","Premature infants","Surfactant therapy","Supraglottic Airway","Laryngeal Mask Airway","Intubation","INSURE","Less Invasive Surfactant Therapy","SALSA","Surfactant via Laryngeal or Supraglottic Airway","RDS","2026-04-17",{"date":150,"type":52},"2026-04-24",{"date":110,"type":21},{"date":153,"type":21},"2029-08-27",{"name":155,"class":156},"Vastra Gotaland Region","OTHER_GOV",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":163,"sex":17,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":60},"100634639","breathing-patterns-in-infants-before-and-after-extubation-100634639","NCT07542301","Breathing Patterns in Infants Before and After Extubation","Inclusion Criteria:\n\n* premature infants (born at ≤32 weeks gestation) who are intubated.\n* medical team is evaluating the baby for extubation readiness\n\nExclusion Criteria:\n\n* Infants with skeletal, neuromuscular, or abdominal surgical disorders that affect the accuracy of RIP measurements will be excluded.",true,"0 Days","6 Months",{"count":167,"type":21},30,"The primary objective of this study is to compare work of breathing indices before and after extubation in intubated premature infants admitted to the Christiana Care Neonatal Intensive Care Unit. The secondary objective is to compare the ability of work of breathing indices to predict extubation failure to routine spontaneous breathing tests (SBTs) in intubated premature infants admitted to the ChristianaCare NICU.",[28,170],"PreTerm Neonate",[172,173,174,175,176],"preterm infants","intubated","respiratory distress","extubation","work of breathing","2026-04-14",{"date":179,"type":52},"2026-04-21",{"date":181,"type":52},"2025-04-14",{"date":183,"type":21},"2026-12",{"name":185,"class":59},"Christiana Care Health Services",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":60},"100627369","phase-2-can-betamethasone-given-after-birth-help-extremely-premature-babies-come-off-breathing-support-safely-and-effectively-100627369","NCT07447739","Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?","Efficacy and Safety of Postnatal Betamethasone for Respiratory Weaning in Extremely Low Gestational Age Neonates (ELGANs) in a Prospective Cohort - Proof of Concept Pilot Study","Inclusion Criteria:\n\n* Infants born at less than 28 weeks gestation age\n* Admitted to WMC NICU prior to day of life 35\n\nExclusion Criteria:\n\n* Infants with major congenital or chromosomal abnormalities.\n* Death prior to DOL 8.\n* Previous exposure to postnatal steroids","28 Weeks",{"count":195,"type":21},100,[197],"PHASE2","The goal of this study is to determine if giving a steroid medication (specifically, betamethasone) after birth can help extremely premature babies (born before 28 weeks) come off breathing machines safely and reduce their risk of chronic lung disease associated with prematurity. Only babies who meet treatment criteria will receive this medication. Babies who do not meet treatment criteria will not receive medication.\n\nThe main questions it aims to answer are:\n\n* Does betamethasone make it easier for babies to come off a breathing machine?\n* Does betamethasone cause any harmful side effects on growth or development?\n\nAll babies in this study will:\n\n* Receive standard NICU care, with or without betamethasone\n* Have their progress, growth, and development followed over time",[28,200],"Bronchopulmonary Dysplasia (BPD)",[202,203,204,205,206],"respiratory distress syndrome","bronchopulmonary dysplasia","extremely low gestational age neonates","postnatal corticosteroids","betamethasone","2026-02-26",{"date":209,"type":52},"2026-03-03",{"date":211,"type":21},"2026-04",{"date":213,"type":21},"2029-03",{"name":215,"class":59},"Khang Nguyen",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100595270","comparing-surfactant-administration-through-supraglottic-airway-and-thin-catheter-for-preterm-infants-100595270","NCT07030270","Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants","A Clinical Trial Comparing Surfactant Administration Through Supraglottic Airway or Thin Catheter for Preterm Infants","SALTI","Inclusion Criteria:\n\n* All preterm infants born at or greater than 29 weeks' gestational age\n* Infants with birthweight greater than or equal to 750 grams and admitted to the NICU on CPAP for respiratory support and qualify for LISA procedure\n\nExclusion Criteria:\n\n* Infants who require intubation prior to surfactant therapy\n* Infants with known severe congenital anomalies (complex congenital heart disease, airway and central nervous system anomalies)\n* Infants whose birth weight is less than 750 grams or oropharynx unable to accommodate laryngeal mask airways","72 Hours",{"count":226,"type":21},40,[24],"What is this study about? This study is comparing two ways of giving surfactant, a medicine that helps premature infants breathe better. Surfactant can be given using a thin tube (\"Less Invasive Surfactant Administration\", called the LISA method) or through a small airway device placed in the baby's throat (\"Surfactant Administration through Laryngeal or Supraglottic Airway\", called the SALSA method). The goal is to see which method is safer and more effective for infants who are born at or after 29 weeks of pregnancy and have trouble breathing.\n\nWhat is the main question (hypothesis)? Infants who receive surfactant using the SALSA method will have fewer breathing-related problems and fewer short-term complications than those who receive it using the LISA method.\n\nWhat are the aims? Aim 1: Are babies in the SALSA group less likely to have low heart rate or low oxygen levels during the procedure compared to babies in the LISA group? Aim 2: Do fewer babies in the SALSA group need to be put on a breathing machine within the first 72 hours of life? Aim 3: Does the SALSA method help reduce the overall time babies need breathing support and lower the cost of their care in the NICU?",[28,101],[172,231,232],"surfactant therapy","respiratory outcomes","2026-02-02",{"date":235,"type":52},"2026-02-04",{"date":237,"type":21},"2026-06-01",{"date":239,"type":21},"2029-06",{"name":241,"class":59},"University of Texas Southwestern Medical Center",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100606137","components-of-mechanical-power-on-the-functional-lung-in-ards-100606137","NCT07171632","Components of Mechanical Power on the Functional Lung in ARDS","Assessment of Mechanical Power Components on the Functional Lung in Patients With Acute Respiratory Distress Syndrome (ARDS)","Inclusion Criteria:\n\n* Patients ≥ 18 years\n* Diagnosis of acute respiratory distress syndrome\n* Receiving invasive mechanical ventilation (volume control mode) for at least 48 consecutive hours.\n\nExclusion Criteria:\n\n* Patients spontaneously breathing\n* Patients under non-invasive support therapies\n* Patients receiving ventilation through a tracheostomy cannula at any time during the first 48 h\n* Patients that receiving pressure-controlled ventilation or any modality other than volume-controlled\n* Patients with missing data for calculating mechanical power (MP).\n* Patients with chronic pulmonary disease\n* Patients with a high risk of death within 3 months for reasons other than ARDS\n* Patients having made the decision to withhold life-sustaining treatment.",{"count":250,"type":21},184,"Mechanical power (MP) is a composite variable that integrates static and dynamic respiratory parameters and has been associated with ventilator-induced lung injury (VILI). MP is predominantly delivered to the reduced functional lung size, commonly referred to as the \"baby lung\" (BL). Functional lung size, in turn, is closely related to respiratory system compliance (Crs). Previous studies have demonstrated an association between MP normalized to compliance (MP\u002FCrs) and mortality. Moreover, evidence suggests that VILI associated with MP\u002FCrs results primarily from the combined effect of its components rather than from any single component in isolation.\n\nThe objective of this study is to evaluate both the overall and the relative contribution of each component of mechanical power, normalized to compliance (MP\u002FCrs), to in-hospital mortality in patients with acute respiratory distress syndrome (ARDS).",[28],"2025-11-26",{"date":255,"type":52},"2025-12-04",{"date":257,"type":21},"2025-12-01",{"date":259,"type":21},"2027-03-10",{"name":261,"class":59},"Ramos Mejía Hospital",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":270,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":60},"100613361","early-prediction-of-lung-injury-in-preterm-infants-score-100613361","NCT07265583","Early Prediction of Lung Injury in Preterm Infants Score","Electrical Impedance Tomography and Lung Ultrasound Score in Early Prediction of Bronchopulmonary Dysplasia in Preterm and Very Low Birth Weight Infants.","EPLIPS","Inclusion Criteria: preterm infants born between 26 and 32 weeks of gestational age and\u002For with a birth weight \\\u003C 1500g (very low birth weight infants - VLBW) with respiratory distress syndrome (RDS).\n\n\\- Exclusion Criteria: - outborn infants\n\n* complex congenital malformations\n* metabolic, chromosomal, or other genetic abnormalities\n* pulmonary hypoplasia, congenital anomalies of surfactant proteins or other pulmonary abnormalities\n* any skin anomalies\n* need for mechanical ventilation \\> 72h after birth\n* any life-threatening comorbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion.\n* lack of parent consent.","26 Weeks","32 Weeks",{"count":273,"type":21},104,"The main hypothesis is that even preterm infants considered \"stable\" receiving non-invasive ventilation may be at risk of developing BPD due to an inhomogeneous distribution of ventilation. Identifying this characteristic from the first days of life by using EIT could, in the future, optimize non-invasive ventilation strategies as early as possible, such as lung recruitment manoeuvres, which are currently mainly used during invasive mechanical ventilation. In addition, comparing the LUS scores and homogeneity parameters derived from the EIT may help to further confirm the role of semi-quantitative lung ultrasound as a rapid, non-invasive, and readily available tool in NICUs for monitoring the lung function of preterm infants in the short and long term.\n\nThe primary objective is to measure homogeneity by Electrical Impedance Tomography (EIT) technology, used in the first weeks of life, for the development of BPD of grade 3, at 36 weeks postmenstrual age or death, in stable preterm infants requiring non-invasive ventilation. The secondary objective are to score if homogeneity at EIT are present and whether if they are associated with BPD. to ompare the distribution of regional lung ventilation obtained by EIT with the validated LUS scores.",[276,277],"Respiratory Distress Syndrome RDS","Preterm Birth",[279,280],"Respiratory distress syndrome RDS","preterm neonate",{"date":282,"type":52},"2025-12-05",{"date":284,"type":52},"2025-10-01",{"date":286,"type":21},"2027-07-01",{"name":288,"class":59},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":306,"locationsCount":4},"100598003","using-artificial-intelligence-models-for-predicting-the-need-for-intubation-and-successful-weaning-from-mechanical-ventilation-in-icu-patients-100598003","NCT07065838","Using Artificial Intelligence Models for Predicting The Need for Intubation and Successful Weaning From Mechanical Ventilation in ICU Patients","Inclusion Criteria\n\n* Adult patients (≥18 years) in ICUs at risk of respiratory failure.\n* Adults (≥18 years) receiving mechanical ventilation for \\>24 hours and deemed ready for weaning.\n\nExclusion Criteria:\n\n* \\- Patients with a pre-existing \"Do Not Intubate\" (DNI) order.\n* \\- Patients with irreversible neurological conditions affecting weaning","90 Years",{"count":297,"type":21},600,"Using artificial intelligence (AI) approach to build a model to determine the optimal timing of intubation and optimal timing of weaning from MV for ICU patients, and compare outcomes with these which depend on clinicians dicision.\n\nAnd also assess whether AI-assisted decisions improve patient outcomes (e.g., reduced intubation delays, shorter ventilation duration).",[28],"2025-07-11",{"date":302,"type":52},"2025-07-15",{"date":284,"type":21},{"date":305,"type":21},"2027-11-01",{"name":307,"class":59},"Assiut University",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":17,"minAge":316,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":60},"100590387","comparison-of-continuous-positive-airway-pressure-cpap-and-non-invasive-positive-pressure-ventilation-nippv-in-preterm-newborns-with-respiratory-distress-syndrome-100590387","NCT06966752","Comparison of Continuous Positive Airway Pressure (CPAP) and Non-Invasive Positive Pressure Ventilation (NIPPV) in Preterm Newborns With Respiratory Distress Syndrome.","Randomized Control Trial: Nasal CPAP vs. NIPPV in Preterm Infants With Respiratory Distress Syndrome","NC3","Inclusion Criteria:\n\n1. gestational age (GA) between 22+0 and 34+6 weeks (estimated on the postmenstrual date and early gestation ultrasonographic findings).\n2. Need of respiratory support (deemed by a clinician).\n\nExclusion Criteria:\n\n1. Major congenital anomalies\n2. Cardiovascular instability\n3. Consent refused or not provided","0 Minutes","44 Weeks",{"count":319,"type":21},150,[24],"Primary objective: to evaluate safety and efficacy of two different non-invasive respiratory support modalities in preterm neonatal patients with respiratory distress syndrome.\n\nSecondary objective is to compare different respiratory support mode performance in different gestational age groups.\n\nPrimary endpoint is treatment failure.\n\nWith this study, the following hypotheses will be tested:\n\nHypothesis 1: NIPPV has a lower failure rate compared to CPAP mode. Hypothesis 2: NIPPV complication rate is non-superior compared to CPAP.",[28],"2025-05-07",{"date":325,"type":52},"2025-05-13",{"date":327,"type":52},"2025-03-25",{"date":329,"type":21},"2027-05-01",{"name":331,"class":59},"Vilnius University",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":339,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":60},"100585349","neonatologist-performed-lung-ultrasound-nplus-to-guide-respiratory-therapy-100585349","NCT06901206","Neonatologist-Performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy","Neonatologist-Performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy on Non-Invasive Ventilation in Preterm Infants","Inclusion Criteria:\n\n* All preterm infants (\\\u003C33 weeks gestational age) from their 2nd week of life, receiving respiratory support via NCPAP\n* expected to stay on NCPAP for the following 5 days at the NICU, Royal Hospital for Women, Randwick, Sydney\n* provided written informed consent obtained from parents.\n\nExclusion Criteria:\n\n* Neonates with previous abdominal surgery\n* Major congenital anomalies.\n* \\>33+0 weeks\n* Less than 1 week of age\n* Invasive ventilation\n* Bilevel or Multilevel non-invasive ventilation\n* Not expected respiratory support via CPAP for the following 5 days.","1 Week",{"count":341,"type":21},20,[24],"The goal of this cross-over clinical trial is to evaluate whether Neonatologist-Performed Lung Ultrasound (NPLUS) can be used in preterm babies on non-invasive breathing support to reduce the amount of oxygen they need. The main question it aims to answer is:\n\nWhen a baby's oxygen requirement goes up, does NPLUS help to target interventions and reduce oxygen requirements?\n\nResearchers will compare NPLUS to standard treatment.\n\nParticipants will:\n\nHave a lung ultrasound performed whenever their oxygen requirement increases by more than 10%.\n\nThe ultrasound findings will be used to target interventions that aim to improve air entry in the lungs.\n\nEach time this happens, the researchers will note what happens to the oxygen requirement afterwards.\n\nEach participant will participate for five days. For the first two days, they will be randomized to either the NPLUS arm or the usual care arm.\n\nThere is then a 24 hour period of usual care. For the final two days, participants cross over to the other arm of the trial.",[170,28],[346,347,348,349,350,351,280,202],"NPLUS","Neonatologist performed lung ultrasound","lung ultrasound score","CPAP","loss of aeration","atelectasis","2025-03-23",{"date":354,"type":52},"2025-03-28",{"date":356,"type":21},"2025-03",{"date":358,"type":21},"2026-06",{"name":360,"class":59},"Royal Hospital For Women",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":163,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":380,"leadSponsor":382,"locationsCount":60},"100575611","serpinb3-expression-par2-and-scca-pd-polymorphism-in-acute-respiratory-distress-syndrome-100575611","NCT06774534","SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome","The ASSESSMENT of SERPINB3 EXPRESSION, PAR2 and SCCA-PD POLYMORPHISM in PATIENTS with ACUTE RESPIRATORY DISTRESS SYNDROME","Serpin-ARDS","Inclusion Criteria:\n\n* ARDS DIAGNOSIS\n* IMV\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy status\n* Lack of consent to participate in the study\n* Contraindications to fiberoptic bronchoscopy and\u002For BAL (bronchoalveolar lavage)\n* Patients with chronic inflammatory skin conditions\n* Patients with chronic lung diseases\n* Patients with inflammatory respiratory diseases\n* Patients with neoplasms such as: squamous cell carcinoma of the cervix, squamous cell carcinoma of the esophagus, lung adenocarcinoma, breast adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma\n* History of active or passive smoking",{"count":226,"type":21},"The Acute Respiratory Distress Syndrome (ARDS) is a systemic syndrome characterized by severe respiratory failure, inflammation, loss of aerated tissue and high mortality. Recently, significant efforts have been made to phenotype ARDS patients through a wide range of new biomarkers and imaging indices with the goal of developing personalized treatments based on patient's biophenotypization. Recent literature demonstrates, both in vitro and in vivo but not yet in ARDS patients, that the serine protease inhibitor(SERPIN)-B3 plays a crucial role in the pathological mechanism of pulmonary fibrogenesis, and, similarly, protease-activated receptors(PAR2) is highly involved in this aberrant inflammatory response.\n\nConsequently, studying the expression of SERPINB3 (including SCCA-PD polymorphism) and PAR2, in association with a detailed clinical and biomolecular phenotypization, could allow new insights into the pathophysiological mechanisms of lung injury during ARDS.",[28,372],"Respiratory Failure",[374,375,43],"ARDS","RESPIRATORY FAILURE","2025-02-28",{"date":378,"type":52},"2025-03-05",{"date":376,"type":52},{"date":381,"type":21},"2030-12-31",{"name":383,"class":59},"University of Padova",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":17,"minAge":316,"maxAge":391,"enrollmentInfo":392,"targetDuration":393,"studyType":71,"phases":4,"briefSummary":394,"conditions":395,"keywords":397,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":410},"100574377","a-prospective-observational-study-of-video-laryngoscopy-versus-direct-laryngoscopy-for-insertion-of-a-thin-endotracheal-catheter-for-surfactant-administration-in-newborn-infants-100574377","NCT06758492","A Prospective Observational Study of Video Laryngoscopy Versus Direct Laryngoscopy for Insertion of a Thin Endotracheal Catheter for Surfactant Administration in Newborn Infants","NEU-VODEtec","Inclusion Criteria:\n\n* newborn infants of any sex who are are having a thin catheter inserted into their trachea for the purpose of surfactant administration\n\nExclusion Criteria:\n\n* no parental consent provided to share their data","28 Days",{"count":297,"type":21},"600 Days","Many premature babies have breathing difficulty after birth and receive help with a breathing machine (nasal continuous positive airway pressure, NCPAP). Some of the babies whose breathing gets worse despite NCPAP are treated with surfactant, a medication that is given directly into their windpipe (trachea). Some of the babies who are given surfactant get it through a ventilation tube (endotracheal tube, ETT), while others get it through a thin catheter that is too small for ventilation. When doctors insert a tube or a thin catheter into the windpipe of a baby, they use an instrument called a laryngoscope, which has a light at its tip, to identify the entrance. Most often doctors look directly into the baby's mouth with a standard laryngoscope to identify the entrance to the windpipe. However, newer video laryngoscopes have a camera along with the light at their tip, which displays a picture of the entrance to the windpipe on a screen. In a study performed at one hospital, doctors inserted an ETT first time more often when they used a video laryngoscope.\n\nThe investigators are doing a study at many hospitals where doctors usually use a standard laryngoscope to insert tubes and thin catheters into a baby's trachea by looking directly into the mouth. Each hospital will switch one-by-one to using a video laryngoscope when inserting a tube. The investigators will compare the information we collect to see if more babies who have a tube inserted first time without falls in their oxygen levels or heart rate with a video laryngoscope. The investigators will also collect information on babies who have a thin catheter inserted to compare whether doctors use fewer attempts when they use a video laryngoscope.",[133,28,396,101],"Video Laryngoscopy",[398,202,399,400],"infant, newborn","surfactant","video laryngoscopy","2025-02-18",{"date":403,"type":52},"2025-02-20",{"date":405,"type":52},"2025-01-13",{"date":407,"type":21},"2025-12-31",{"name":409,"class":59},"University College Dublin",16,{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":60},"100576321","study-on-the-correlation-between-tracheotomy-tip-pressure-and-esophageal-pressure-in-patients-weaned-from-tracheotomy-100576321","NCT06783777","Study on the Correlation Between Tracheotomy Tip Pressure and Esophageal Pressure in Patients Weaned from Tracheotomy","Inclusion Criteria:\n\n* Adult patients (≥18 years old), regardless of gender\n* Tracheostomized patients with spontaneous breathing;\n* Weaning criteria: under the condition of mask oxygen inhalation at 5L\u002Fmin, SPO2 \\> 94%, PaO2\u002FFiO2 \\> 150 - 200.\n* The patient has stable hemodynamics and pH ≥ 7.32;\n* Agree to participate in this trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with contraindications for esophageal catheter insertion and unable to monitor esophageal pressure;\n* Patients with bleeding risks: severe coagulation disorders, esophageal varices；\n* Local injuries: basilar skull fracture, maxillofacial fracture;\n* Pregnant women;\n* Patients considered not suitable by the researcher.","99 Years",{"count":419,"type":21},42,[24],"Whether the correlation between gas incision tip pressure fluctuations (ΔPtt) and esophageal pressure fluctuations (ΔPes) is a potential measure of spontaneous respiratory effort in patients undergoing gas incision offline.",[28,423],"Respiratory Ilness",[425,426],"esophageal-pressure","tracheotomy tip pressure","2025-01-15",{"date":429,"type":52},"2025-01-20",{"date":431,"type":21},"2025-02-05",{"date":433,"type":21},"2026-12-26",{"name":435,"class":59},"Shanghai Zhongshan Hospital"]